307 related articles for article (PubMed ID: 27154025)
1. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
Cosmai L; Gallieni M; Liguigli W; Porta C
J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
[TBL] [Abstract][Full Text] [Related]
3. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
4. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
Roodhart JM; Langenberg MH; Witteveen E; Voest EE
Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
6. Vascular Endothelial Growth Factor Inhibitor Therapy and Cardiovascular and Renal Damage in Renal Cell Carcinoma.
Lai S; Molfino A; Seminara P; Longo F; Innico G; Coppola B; Mastroluca D; Galani A; Dimko M; Aceto P; Lai C
Curr Vasc Pharmacol; 2018 Jan; 16(2):190-196. PubMed ID: 28676023
[TBL] [Abstract][Full Text] [Related]
7. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
Izzedine H
Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
[TBL] [Abstract][Full Text] [Related]
8. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.
Tesařová P; Tesař V
Folia Biol (Praha); 2013; 59(1):15-25. PubMed ID: 23537524
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
Takahashi S
Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
Ko HT; Yin JL; Wyburn K; Wu H; Eris JM; Hambly BD; Chadban SJ
Nephrol Dial Transplant; 2013 Feb; 28(2):327-36. PubMed ID: 23229928
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
Izzedine H; Rixe O; Billemont B; Baumelou A; Deray G
Am J Kidney Dis; 2007 Aug; 50(2):203-18. PubMed ID: 17660022
[TBL] [Abstract][Full Text] [Related]
13. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.
Versmissen J; Mirabito Colafella KM; Koolen SLW; Danser AHJ
Cardiovasc Res; 2019 Apr; 115(5):904-914. PubMed ID: 30726882
[TBL] [Abstract][Full Text] [Related]
14. Proteinuria and VEGF-targeted therapies:
an underestimated toxicity?
Izzedine H; Soria JC; Escudier B
J Nephrol; 2013; 26(5):807-10. PubMed ID: 24052461
[TBL] [Abstract][Full Text] [Related]
15. Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine.
Zhang C; Wang N; Tan HY; Guo W; Li S; Feng Y
Integr Cancer Ther; 2018 Sep; 17(3):582-601. PubMed ID: 29807443
[TBL] [Abstract][Full Text] [Related]
16. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
Vigneau C; Rioux-Leclercq N
Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
[TBL] [Abstract][Full Text] [Related]
17. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
Eskens FA; Verweij J
Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419
[TBL] [Abstract][Full Text] [Related]
18. [Anticancer drugs under pressure].
Ben Aïssa A; George AC; El M'Rabet FZ; Mach N; Dietrich PY; Pechère-Bertschi A
Rev Med Suisse; 2011 Sep; 7(308):1761-6. PubMed ID: 21954818
[TBL] [Abstract][Full Text] [Related]
19. VEGF signal system: the application of antiangiogenesis.
Liang X; Xu F; Li X; Ma C; Zhang Y; Xu W
Curr Med Chem; 2014 Mar; 21(7):894-910. PubMed ID: 24059233
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1.
Lankhorst S; Kappers MH; van Esch JH; Danser AH; van den Meiracker AH
J Hypertens; 2013 Mar; 31(3):444-54; discussion 454. PubMed ID: 23221987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]